## [1] 0.2399036
Treat as binary outcome
Plot all junction discovery rates in each condition and tissue
##
## Fisher's Exact Test for Count Data
##
## data: table(stmn2 = ftd_c9$stmn2_data, c9 = ftd_c9$reported_mutations)
## p-value = 1
## alternative hypothesis: true odds ratio is not equal to 1
## 95 percent confidence interval:
## 0.2121109 4.8153877
## sample estimates:
## odds ratio
## 0.9276436
In both Cervical and Lumbar Spinal Cord, donors with detectable tSTMN2 have a later age of onset and a shorter length of time with the disease.
What do we make of this? ALS can be a rapidly progressing disease and this is often seen in early onset cases. However lots of early-onset cases have a slowly progressing disease course.
If we are more likely to observe tSTMN2 in cases that had a later disease onset but shorter disease course, what does this mean? Shorter disease course could mean either a more rapid progression or less time for motor neurons to get TDP pathology and die before the patient themselves die, perhaps of complications. We would need more clinical information (staging, measures of decline over time) to properly assess this.
Age of disease onset information is not provided for FTLD-TDP samples